Debanjan Ray, Synthekine CEO

Sanofi part­ners with Syn­thekine in im­munol­o­gy race

Syn­thekine is team­ing up with Sanofi in a $40 mil­lion-plus col­lab­o­ra­tion to de­vel­op IL-10 re­cep­tor ag­o­nists for au­toim­mune and in­flam­ma­to­ry dis­eases.

The cy­tokine-fo­cused biotech will re­ceive the $40 mil­lion up­front with the po­ten­tial for undis­closed ad­di­tion­al pre­clin­i­cal, de­vel­op­ment, reg­u­la­to­ry and com­mer­cial mile­stones, as well as tiered roy­al­ties on net sales. Sanofi will take over clin­i­cal and com­mer­cial ac­tiv­i­ties for se­lect­ed ag­o­nists.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.